Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
sabato, ottobre 24
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Ligand Pharmaceuticals Inc
LGND
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$303.53
-4.29
-1.39%
Ult. Agg.: Oct 23, 4:00 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 tra 5 giorni da adesso in gio ott 29th, prima dell'apertura del mercato
Conference call:
Conference call programmata per tra 5 giorni alle 8:30 AM
Clicca per vedere il webcast
Ligand Pharmaceuticals Financials
Ligand Pharmaceuticals (LGND) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $288.559M Est
Ligand Pharmaceuticals (NASDAQ:LGND) raises FY2026 Adj EPS guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$310.000 million to $270.000
Benzinga Newsdesk
PRO
Ligand Pharmaceuticals Q2 Adj. EPS $2.37 Beats $1.84 Estimate, Sales $63.693M Beat $60.765M Estimate
Benzinga Newsdesk
PRO
Ligand Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $8.50-$9.50 vs $9.13 Est; Affirms FY2026 Sales Guidance of $270.000M-$310.000M vs $281.535M Est
Ligand Pharmaceuticals (NASDAQ:LGND) affirms FY2026 Adj EPS guidance from $8.50-$9.50 to $8.50-$9.50 vs $9.13 analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$310.000 million to $270.000
Benzinga Newsdesk
PRO
Ligand Pharmaceuticals Q1 Adj. EPS $1.63 Misses $1.82 Estimate, Sales $51.722M Miss $58.696M Estimate
Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.63 per share which missed the analyst consensus estimate of $1.82 by 10.44 percent. This is a 22.56 percent increase over earnings of $1.33 per share
Benzinga Newsdesk
PRO
Earlier Monday, Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.00-$9.00 to $8.50-$9.50 vs $9.40 Est; Raises FY2026 Sales Guidance from $245M-$285M to $270M-$310M vs $266.714M Est
Benzinga Newsdesk
PRO
Ligand Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $8.00-$9.00 vs $8.29 Est; Affirms FY2026 Sales Guidance of $245.000M-$285.000M vs $265.679M Est.
Ligand Pharmaceuticals (NASDAQ:LGND) affirms FY2026 Adj EPS guidance from $8.00-$9.00 to $8.00-$9.00 vs $8.29 analyst estimate. Affirms FY2026 sales outlook from $245.000 million-$285.000 million to $245.000
Benzinga Newsdesk
